NCT06146127 (PREMED-CHC) is a clinical trial of phenotyping in Liver Cancer, sponsored by Inserm U955.

Who is sponsoring NCT06146127?

NCT06146127 is sponsored by Inserm U955.

What drugs are being tested in NCT06146127?

Interventions in NCT06146127: phenotyping.

What condition does NCT06146127 study?

NCT06146127 studies Liver Cancer.

Is NCT06146127 still recruiting?

NCT06146127 is currently status unknown. Last updated 24 November 2023.

Last reviewed 2023-11-24 · How we verify

NCT06146127: PREMED-CHC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma

Status unknown Last updated 24 November 2023

What this trial tests

trial testing phenotyping in Liver Cancer in 300 participants. Status unknown.

Timeline

15 January 2001

Primary endpoint
15 January 2023

30 January 2025

Quick facts

Lead sponsor	Inserm U955
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	300
Start date	15 January 2001
Primary completion	15 January 2023
Estimated completion	30 January 2025
Sites	1 location across France

Drugs / interventions tested

phenotyping — full drug profile →

Conditions studied

Liver Cancer — all drugs for Liver Cancer →

Sponsor

Inserm U955

Who can join

18 and older, any sex, with Liver Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our project is a large-scale characterisation of cHCC-CCA will allow us to determine which subsets harbor actionable gene alterations. We will also aim to improve diagnosis of this tumor type by the use of immunohistochemical biomarkers and the development of deep-learning based models able to help cHCC-CCA diagnosis. This will represent an important step towards precision medicine for the patients with this highly aggressive malignancy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Liver Cancer

Currently open trials in the same condition.

NCT07295275 — Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection · recruiting
NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07295340 — Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection · recruiting
NCT07504367 — Large Language Models Assist in Tumor MDT · NA · recruiting
NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06146127 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Inserm U955
Last refreshed: 24 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06146127.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing